Cargando…

Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with poor prognosis and access to anti-HER2 treatment is still a challenge in lower-middle income countries. The availability of the biosimilar trastuzumab has improved access by lowering the costs. We r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joel, Anjana, Georgy, Josh Thomas, Thumaty, Divya Bala, John, Ajoy Oommen, Chacko, Raju Titus, Rebekah, Grace, Sigamani, Elanthenral, Chandramohan, Jagan, Manipadam, Marie Therese, Cherian, Anish Jacob, Abraham, Deepak Thomas, Jacob, Paul Mazhuvanchary, Sebastian, Patricia, Backianathan, Selvamani, Singh, Ashish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057782/ https://www.ncbi.nlm.nih.gov/pubmed/33912232 http://dx.doi.org/10.3332/ecancer.2021.1207

Ejemplares similares

Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma
por: Thumaty, Divya Bala, et al.
Publicado: (2021)

Intercycle Unplanned Hospital Admissions Due to Cisplatin-based Chemotherapy Regimen-induced Adverse Reactions: A Retrospective Analysis
por: Bright, Heber Rew, et al.
Publicado: (2019)

Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: Prevalence, risk factors, cost and effect on disease outcome
por: Sharma, Parth, et al.
Publicado: (2022)

End-of-Treatment FDG PET-CT (EOT-PET) in Patients with Post-Chemotherapy Masses for Seminoma: Can We Avoid Further Intervention?
por: Joel, Anjana, et al.
Publicado: (2022)

Is TIRADS a practical and accurate system for use in daily clinical practice?
por: Chandramohan, Anuradha, et al.
Publicado: (2016)

Nanotechnology in oncology: Characterization and in vitro release kinetics of cisplatin-loaded albumin nanoparticles: Implications in anticancer drug delivery
por: Das, Saikat, et al.
Publicado: (2011)

Primary mediastinal germ cell tumours: real world experience in the low middle income (LMIC) setting
por: Joel, Anjana, et al.
Publicado: (2021)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Physicochemical and Biological Characterization of a Biosimilar Trastuzumab
por: López-Morales, Carlos A., et al.
Publicado: (2015)

Neurocutaneous Melanosis with Leptomeningeal Melanoma Involving Supratentorium and Infratentorium
por: Thomas, Solly, et al.
Publicado: (2018)

Presurgical Screening of Fine Needle Aspirates from Thyroid Nodules for BRAF Mutations: A Prospective Single Center Experience
por: Hemalatha, Ramamoorthy, et al.
Publicado: (2018)

Special AT-rich sequence-binding protein 2 (SATB2) in the differential diagnosis of osteogenic and non-osteogenic bone and soft tissue tumors
por: Milton, Sharon, et al.
Publicado: (2022)

Peripheral T cell lymphoma: Clinico-pathological characteristics & outcome from a tertiary care centre in south India
por: Nemani, Sandeep, et al.
Publicado: (2018)

Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
por: Jassem, Shea, et al.
Publicado: (2019)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin(®))
por: Hurst, Susan, et al.
Publicado: (2014)

Can we establish a hierarchy among trastuzumab biosimilar candidates?
por: Pivot, Xavier, et al.
Publicado: (2018)

Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
por: Paek, Kyungyeol, et al.
Publicado: (2019)

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
por: Triantafyllidi, Eleni, et al.
Publicado: (2022)

Paraneoplastic Pemphigus Associated with Follicular Dendritic Cell Tumor in the Mediastinum
por: Prakasan, Aparna Mullangath, et al.
Publicado: (2016)

Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
por: Barat, Eric C., et al.
Publicado: (2023)

In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate
por: Chen, Liuxi, et al.
Publicado: (2016)

Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
por: Hutterer, Katariina M., et al.
Publicado: (2019)

Is hemi-thyroidectomy adequate in low risk differentiated thyroid cancer?
por: Benjamin, Justin, et al.
Publicado: (2019)

Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars
por: Azuz, Samuel, et al.
Publicado: (2021)

Radiotherapeutic management of brain tumours during the COVID-19 pandemic
por: Balakrishnan, Rajesh, et al.
Publicado: (2020)

Cutaneous metastasis from testicular germ cell tumour
por: Joel, Anjana, et al.
Publicado: (2014)

Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization
por: Miranda-Hernández, Mariana P., et al.
Publicado: (2015)

Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
por: Kim, Seokkyun, et al.
Publicado: (2017)

Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
por: Moghimi, Minoosh, et al.
Publicado: (2021)

Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
por: Kolberg, Hans-Christian, et al.
Publicado: (2021)

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
por: Jang, Minyoung, et al.
Publicado: (2020)

The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
por: Barszczewska, Olga, et al.
Publicado: (2021)

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab
por: Yang, Charlie, et al.
Publicado: (2022)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

No impact of dietary iodine restriction in short term development of hypothyroidism following fixed dose radioactive iodine therapy for Graves’ disease
por: Jacob, Jubbin Jagan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ek4oifp60nv505uf61kfgkec4k